Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to viral- 67% Improvement Relative Risk Time to viral- (b) 59% Huang et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 373 patients in China Faster viral clearance with HCQ (p=0.0001) Huang et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113 Favors HCQ Favors control
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Huang et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113
Huang et al., Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of.., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113
May 2020   Source   PDF  
  All Studies   Meta
197 CQ patients, 176 control. Mean time to undetectable viral RNA and duration of fever significantly reduced. No serious adverse events.
time to viral-, 67.0% lower, relative time 0.33, p < 0.001, treatment 197, control 176.
time to viral-, 59.1% lower, relative time 0.41, p < 0.001, treatment 32, control 37, early treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 28 May 2020, prospective, China, peer-reviewed, 36 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: National Science Review 7: 1428–1436, 2020 doi: 10.1093/nsr/nwaa113 Advance access publication 28 May 2020 RESEARCH ARTICLE (Continued on next page) ∗ Corresponding authors. E-mails: pei;;;;; † Equally contributed to this work. Received 19 April 2020; Revised 8 May 2020; Accepted 10 May 2020 CLINICAL MEDICINE Special Section: SARS-CoV-2 Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 Mingxing Huang1,† , Man Li2,3,† , Fei Xiao1,2,† , Pengfei Pang2,3,† , Jiabi Liang4,† , Tiantian Tang5,† , Shaoxuan Liu6 , Binghui Chen7 , Jingxian Shu4 , Yingying You8 , Yang Li2,3 , Meiwen Tang9 , Jianhui Zhou10 , Guanmin Jiang10 , Jingfen Xiang11 , Wenxin Hong12 , Songmei He13 , Zhaoqin Wang14 , Jianhua Feng15 , Changqing Lin16 , Yinong Ye17 , Zhilong Wu18 , Yaocai Li19 , Bei Zhong20 , Ruilin Sun21 , Zhongsi Hong1 , Jing Liu22 , Huili Chen1 , Xiaohua Wang23 , Zhonghe Li24 , Duanqing Pei25,26,∗ , Lin Tian3,∗ , Jinyu Xia1,∗ , Shanping Jiang5,∗ , Nanshan Zhong27,∗ and Hong Shan2,3,∗ ABSTRACT Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19. In this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500 mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events. A total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians −6.0 days; 95% CI −6.0 to −4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. Although randomized trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic. Keywords: COVID-19, SARS-CoV-2, treatment, chloroquine
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop